Banerjee Subhashis
Banerjee Subhashis, CMO, reported a transaction classified as exercise at Artiva Biotherapeutics, Inc. involving 5306.000000 shares for an estimated $10187.52. Reported holdings after the transaction were 150269.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Aug 27, 2026
- Filing date
- Aug 31, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
ARTV price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001193125-26-377207 Common Stock
- Transaction date
- Aug 27, 2026 Filed Aug 31, 2026, 11:06 PM · 4d delay
- Shares
- 5,306 sh $1.92 per share
- Estimated value
- $10.1k Computed from shares × price
- Holdings after
- 150,269 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-4 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Medical Officer
- F1
The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.
- F2
The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security…
- F3
25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of…
0 other transactions
0 recent txs